Clinical Trial Update: First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590) [Phase 3]

View source ↗

Summary

Phase 3 study MK-3475-590 (KEYNOTE-590) evaluating pembrolizumab plus chemotherapy versus chemotherapy in first-line esophageal neoplasms has completed; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Neoplasms

Drugs mentioned

• Keytruda (Pembrolizumab) (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Esophageal Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2021-07-06